 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...170171172173174175176177178179180...235236» |
- | leucovorin calcium / generics, methotrexate / generics
Journal: Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Anti-proliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP. (Pubmed Central) - May 29, 2019
Together, these findings demonstrate that increased MTX activity with decreased NAMPT expression is dependent on the anti-folate activity of MTX, and is driven by enhanced sensitivity to the ATP-depleting effects of MTX. For the first time, these findings provide mechanistic details to explain the increase in pharmacological activity of MTX under conditions of reduced NAMPT activity.
- | Bevax (bevacizumab biosimilar) / Amneal, mAbxience, Libbs Farmacêutica
Clinical, Journal, Combination therapy: Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. (Pubmed Central) - May 29, 2019
P1
For the first time, these findings provide mechanistic details to explain the increase in pharmacological activity of MTX under conditions of reduced NAMPT activity. Our results suggest that BEVZ92 and reference bevacizumab are pharmacokinetically bioequivalent and have no appreciable differences in safety profiles as first-line treatment in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Journal: A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. (Pubmed Central) - May 29, 2019
We report a case of an 83-year-old Hispanic man, non-smoker, with KRAS/NRAS wild-type mCRC of the liver who was treated with 9 cycles of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) and cetuximab...We aim to highlight the risk of severe life-threatening ILD associated with panitumumab. Early recognition of this serious adverse event helps avoid unnecessary administration of systemic antibiotics and prevent mortality.
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Enrollment change, Metastases: An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - May 29, 2019
P=N/A, N=1376, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Early recognition of this serious adverse event helps avoid unnecessary administration of systemic antibiotics and prevent mortality. Active, not recruiting --> Completed | N=2000 --> 1376
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - May 29, 2019
P3, N=1400, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=2000 --> 1376 Suspended --> Active, not recruiting
- ||||||| andecaliximab (GS-5745) / Gilead
Trial completion, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 28, 2019
P3, N=432, Completed, Sponsor: Gilead Sciences
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Clinical, P3 data, Journal: Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. (Pubmed Central) - May 26, 2019
P3
Active, not recruiting --> Completed A limited but consistent benefit on both OS and PFS was associated with the addition of aflibercept to FOLFIRI compared with placebo in patients <65 and ≥65years old, with a marked but manageable increase in the toxicity profile in older patients.
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer. (Pubmed Central) - May 26, 2019
Multivariate Cox regression analysis revealed that sex, tumor size, pre‑treatment BA count and the post‑/pre‑treatment NE ratio were independent prognostic factors affecting OS. The results of the present study suggested that the pre‑treatment BA count and post‑/pre‑treatment NE ratio may be potential prognostic factors for resectable colorectal cancer.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Clinical, Journal, Real-World Evidence: Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. (Pubmed Central) - May 25, 2019
However, neutropenia, anemia, fatigue, and vomiting were statistically increased in the 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose of FOLFIRINOX (p<0.05). This study demonstrates the efficacy and tolerability of modified FOLFIRINOX in advanced and metastatic pancreatic cancer.
- | Clinical, Journal: Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. (Pubmed Central) - May 23, 2019
Our study suggests that preoperative FLOT chemotherapy is safe and feasible. In terms of OS, FLOT may be superior to initial surgery followed by chemotherapy in reducing morbidity with resectable LAGC.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma (clinicaltrials.gov) - May 22, 2019
P3, N=900, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Review, Journal: Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. (Pubmed Central) - May 22, 2019
In selected patients, adjuvant modified FOLFIRINOX can produce a 5-year survival rate of around 50%. Further potential gains are to be made in the selection of patients for particular therapies based on the transcriptomic and genetic signature of individual tumors.
- |||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 21, 2019
P2, N=105, Not yet recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
New P3 trial: AALL1732: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (clinicaltrials.gov) - May 21, 2019
P3, N=3698, Not yet recruiting, Sponsor: Children's Oncology Group
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy (clinicaltrials.gov) - May 21, 2019
P3, N=1580, Active, not recruiting, Sponsor: Samsung Medical Center
Further potential gains are to be made in the selection of patients for particular therapies based on the transcriptomic and genetic signature of individual tumors. Recruiting --> Active, not recruiting | N=2660 --> 1580 | Trial primary completion date: Dec 2018 --> Dec 2019
- ||| Aphexda (motixafortide) / BioLineRx, Ayrmid
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - May 21, 2019
P2a, N=80, Recruiting, Sponsor: BioLineRx, Ltd.
Recruiting --> Active, not recruiting | N=2660 --> 1580 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Recruiting | Phase classification: P2 --> P2a | N=37 --> 80 | Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Jun 2018 --> Dec 2021
- || eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Enrollment change, Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - May 21, 2019
P1, N=155, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Recruiting | Phase classification: P2 --> P2a | N=37 --> 80 | Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Jun 2018 --> Dec 2021 N=235 --> 155 | Trial completion date: Feb 2021 --> Jul 2020 | Trial primary completion date: Feb 2021 --> Jul 2020
- | Vectibix (panitumumab) / Amgen
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver (clinicaltrials.gov) - May 21, 2019
P2, N=0, Withdrawn, Sponsor: Memorial Sloan Kettering Cancer Center
N=235 --> 155 | Trial completion date: Feb 2021 --> Jul 2020 | Trial primary completion date: Feb 2021 --> Jul 2020 N=80 --> 0 | Trial completion date: Feb 2020 --> May 2019 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2020 --> May 2019
- | Stivarga (regorafenib) / Bayer
Enrollment open, Combination therapy, Metastases: FOLFIRINOX-R: Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (clinicaltrials.gov) - May 20, 2019
P1/2, N=87, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
N=80 --> 0 | Trial completion date: Feb 2020 --> May 2019 | Recruiting --> Withdrawn | Trial primary completion date: Feb 2020 --> May 2019 Not yet recruiting --> Recruiting
- ||| gevokizumab (VPM087) / Novartis
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov) - May 20, 2019
P1, N=172, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> May 2022
- || Hepacid (pegargiminase) / Polaris Pharma
Trial completion date, Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - May 20, 2019
P1/2, N=225, Recruiting, Sponsor: Polaris Group
Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> May 2022 Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date, Gene Expression Profile: A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile (clinicaltrials.gov) - May 20, 2019
P=N/A, N=2660, Active, not recruiting, Sponsor: Samsung Medical Center
Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Apr 2020 | Trial primary completion date: Dec 2017 --> Dec 2019
- | Jakafi (ruxolitinib) / Incyte
Trial completion date: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 20, 2019
P2, N=92, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Apr 2018 --> Apr 2020 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial completion date: Jul 2023 --> Jul 2024
- | Trial completion date, Trial primary completion date, Metastases: FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study (clinicaltrials.gov) - May 20, 2019
P2, N=38, Not yet recruiting, Sponsor: Samsung Medical Center
Trial completion date: Jul 2023 --> Jul 2024 Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2017 --> Dec 2021
- | vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: MP-PDAC-01: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - May 20, 2019
P1b, N=36, Not yet recruiting, Sponsor: Joon Oh Park
Trial completion date: Dec 2018 --> Dec 2021 | Trial primary completion date: Dec 2017 --> Dec 2021 Trial completion date: Dec 2019 --> Dec 2020 | Initiation date: Sep 2018 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Sep 2020
- ||| Enrollment closed, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - May 17, 2019
P1b/2, N=332, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Dec 2019 --> Dec 2020 | Initiation date: Sep 2018 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Sep 2020 Recruiting --> Active, not recruiting
- || Enrollment closed: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - May 17, 2019
P1/2, N=79, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || dalutrafusp alfa (AGEN1423) / Agenus
New P1 trial, Combination therapy, Monotherapy, Metastases: Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 16, 2019
P1, N=33, Not yet recruiting, Sponsor: Gilead Sciences
- | Trial termination, Metastases: E-DIS: Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (clinicaltrials.gov) - May 16, 2019
P2, N=105, Terminated, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- | NN1213 / Novo Nordisk
Enrollment closed, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - May 16, 2019
P2, N=126, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- | leucovorin calcium / Generic mfg.
Clinical, P1 data, Journal: Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. (Pubmed Central) - May 15, 2019
However, although objective responses were observed, this combination was not significantly better than our prior approaches. Further treatment intensification strategies, including individualized dose escalation for radiation-tolerant livers, and improved radiosensitization should be investigated, along with improved systemic therapy.
- | Clinical, P2 data, Journal: Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma. (Pubmed Central) - May 15, 2019
The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.
- | Biomarker, Enrollment closed, Trial primary completion date, Metastases: PAMELA70: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 15, 2019
P2, N=72, Active, not recruiting, Sponsor: Institut Cancerologie de l'Ouest
http://creativecommons.org/licenses/by-nc-nd/4.0/. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Jul 2019
- | Trial completion date, Trial primary completion date: PROTECT: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (clinicaltrials.gov) - May 15, 2019
P2, N=106, Recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Oct 2018 --> Jun 2023 | Trial primary completion date: Apr 2018 --> Jun 2022
- | leucovorin calcium / generics
Journal: A bacterial route for folic acid supplementation. (Pubmed Central) - May 15, 2019
Folic acid supplementation in C. elegans occurs chiefly indirectly via bacterial uptake of breakdown products via E. coli AbgT, and can impact C. elegans development and longevity. Examining how folic acid supplementation affects bacterial folate synthesis in the human gut may help us to better understand the safety of folic acid supplementation.
- | leucovorin calcium / Generic mfg., temozolomide / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: FOLAGLI: Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma (clinicaltrials.gov) - May 14, 2019
P1, N=30, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
Examining how folic acid supplementation affects bacterial folate synthesis in the human gut may help us to better understand the safety of folic acid supplementation. N=44 --> 30 | Trial completion date: Mar 2018 --> Sep 2021 | Trial primary completion date: Mar 2017 --> Sep 2020
- | Enrollment change, Trial withdrawal: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (clinicaltrials.gov) - May 14, 2019
P2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=44 --> 30 | Trial completion date: Mar 2018 --> Sep 2021 | Trial primary completion date: Mar 2017 --> Sep 2020 N=376 --> 0 | Not yet recruiting --> Withdrawn
- ||| Bavencio (avelumab) / EMD Serono, Herceptin (trastuzumab) / Roche
Enrollment open: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (clinicaltrials.gov) - May 13, 2019
P2, N=63, Recruiting, Sponsor: Michael Sangmin Lee
N=376 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- || Enrollment closed, Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - May 13, 2019
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019
- || Enrollment closed: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - May 13, 2019
P1b/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019 Recruiting --> Active, not recruiting
- ||| Enrollment closed, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - May 13, 2019
P1/2, N=382, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || onvansertib (PCM-075) / Cardiff Oncology
Enrollment open, Combination therapy, Metastases: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (clinicaltrials.gov) - May 12, 2019
P1b/2, N=44, Recruiting, Sponsor: Trovagene, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Soliris (eculizumab) / Alexion Pharma
Journal: Paroxysmal nocturnal hemoglobinuria. (Pubmed Central) - May 11, 2019
Patients with severe hemo-lysis and/or thrombotic complications are indicated for administration of eculizumab - a monoclonal antibody against C5 part of complement. Key words: diagnosis - eculizumab - immunosuppression - paroxysmal nocturnal hemoglobinuria - pathogenesis - transplantation - treatment.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Journal: Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. (Pubmed Central) - May 10, 2019
The classification of patients based on resectability was predictive of actual resection rates as well as outcomes. Signet ring mRC show inferior outcomes in this cohort of patients.
- || Trial completion date, Trial primary completion date: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - May 10, 2019
P2, N=300, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Signet ring mRC show inferior outcomes in this cohort of patients. Trial completion date: Nov 2019 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Nov 2020
- | Avastin (bevacizumab) / Roche
Trial completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - May 10, 2019
P1/2, N=13, Completed, Sponsor: Sofya Pintova
Trial completion date: Nov 2019 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Nov 2020 Trial completion date: Jan 2017 --> Oct 2018
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma (clinicaltrials.gov) - May 9, 2019
P2, N=26, Recruiting, Sponsor: Fujian Cancer Hospital
Trial completion date: Jan 2017 --> Oct 2018 Not yet recruiting --> Recruiting
- | Enrollment open: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer (clinicaltrials.gov) - May 9, 2019
P3, N=600, Recruiting, Sponsor: Fujian Cancer Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - May 9, 2019
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
- | Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: TIME-PRODIGE 28: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - May 9, 2019
P2, N=134, Recruiting, Sponsor: UNICANCER
Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Trial completion date: Jun 2020 --> Mar 2022 | Trial primary completion date: Feb 2018 --> Oct 2019